[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_591 

# __Pathogenesis__

## Articles mentionning this Benefit

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_118.md)

## Category to which it belongs

* [Effective control and elimination of infectious pathogens to prevent disease transmission and reduce the overall risk of infection.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_1.md)

## Description of actual returns pertaining to this benefit

* [Asset value increase from improved treatment options](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_645.md)

## Name of the Benefit

Identification of targets for therapeutic intervention

## Risks which can benefit from this action

* [Ace2 and tmprss2 inhibitors](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_595.md)

## Stakeholders benefitting from this Benefit

* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)

